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ABSTRACT
We evaluated the number and types of particles in glycyrrhizin injections after ampoule cutting. A total of 100 glass
ampoules of 5 companies were examined. The mean number of particles with diameter of 1.3- < 5 µm was 252.9/mL, and that of
particles with diameter of 5- < 10 µm was 12.5/mL. The number of particles differed among products of the 5 companies, e.g., the
number of particles with a diameter of 1.3- < 5 µm varied from 351.9/mL to 121.6/mL. In addition, a total of 120 plastic ampoules
from 6 companies were evaluated. The mean number of particles with a diameter of 1.3- < 5 µm was 43.0/mL, and that of particles
with a diameter of 5- <10 µm was 2.1/mL. Differences among products of the 6 companies were not siqnificant. The number of
particles in glycyrrhizin injections after ampoule cutting was significantly lower in plastic than for glass ampoules ( p < 0.0001).
Scanning electron microscopy and X-ray microanalysis identified glass fragments in glycyrrhizin injection samples after the
cutting of glass ampoules but identified no particles after cutting plastic ampoules. Glycyrrhizin injections are commonly used
in Asia including Japan, Taiwan, and China. The use of plastic ampoules is recommended for the prevention of the entry of glass
fragments into the body.
Key words: particulate contamination, glycyrrhizin injection, glass ampoule, plastic ampoule, glass fragment

INTRODUCTION
Particles such as glass fragments in injections not
only damage the brain, liver, and kidneys but also cause
pulmonary embolism(1-8). Therefore, the measures of
specific contamination for injections are important, and
so are the use of inline filters during intravenous drip
infusion and membrane filters at the time of the preparation of drugs for injection. However, the use of inline
filters or membrane filters is expensive and time-consuming. In many hospitals, inline filters are used only during
total parenteral nutrition, and membrane filters are used
only for the preparation of anticancer drugs in pharmacies. Thus, the measures of particulate contamination
for injections are usually taken only at the time of total
parenteral nutrition or the administration of anticancer
drugs, while no measures are taken for drugs administered via a peripheral vein.
A commonly used injection is glycyrrhizin solution. Since glycyrrhizin injections are administered via
a peripheral vein, inline filters are not currently used.
* Author for correspondence. Tel: +81-834-61-2500;
Fax: +81-834-61-2501; E-mail: yorioka-reywal@ric.hi-ho.ne.jp

In addition, the administration volume of this injection
is 40-100 mL (2-5 ampoules), and long-term administration daily or 2-3 times/day is performed. When glass
ampoules of glycyrrhizin injections are used, a large
amount of glass fragments after ampoule cutting may
enter the blood vessel. Therefore plastic ampoules of
glycyrrhizin injections have become commercially available. However, since no studies have compared particles
in this agent between glass and plastic ampoules, the
usefulness of plastic ampoules has not yet been established. In this study, we compared particle contamination in glycyrrhizin injections between glass and plastic
ampoules after ampoule cutting.

MATERIALS AND METHODS
The numbers, diameters, and types of particles in
glass ampoules 20 mL glycyrrhizin injections (n = 100)
and plastic ampoules 20 mL glycyrrhizin (n=120) were
evaluated (total, 220 samples). The glass ampoules were
Stronger Neo-Minophagen® C (Company A, n = 20),
Neophagen® C (Company B, n = 20), Glyveltin® (Compa-
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ny C, n = 20), Kalosgen® (Company D, n = 20), and
Kyominotin® (Company E, n = 20). The plastic ampoules
were Stronger Neo-Minophagen® P (Company A, n =
20), Neophagen® (Company B, n = 20), Glyphagen C®
(Company F, n = 20), Gulucolin S® (Company G, n = 20),
Hishiphagen C® (Company H, n = 20), and Asphagen®
(Company I, n = 20). Glycyrrhizin injections of the same
lot of each pharmaceutical company were used. All glass
ampoules were of the one-point cut type.
Samples were obtained by the following methods. Glass or plastic ampoules were cut and left for 3
minutes. Subsequently, a 10 mL injection sample was
collected from the inside of the ampoule. These procedures were performed in a safety cabinet. The size and
number of particles in samples after glass or plastic
ampoules cutting were measured using a light blockage
counter KL-04 (Rion K. K., Tokyo, Japan). Particles after
ampoule cutting were counted using the first method
(light blockage particle counting: light blockage counter
KL-04) of the Foreign Insoluble Matter Test for Injection mentioned by the Pharmacopoeia of Japan, which
was also used for particle counting in injections before
ampoule cutting.
Glycyrrhizin solutions after ampoules cutting were
filtrated through a 0.22 µm membrane filter (Nippon

Becton Dickinson Co., Tokyo, Japan) in a safety cabinet.
The particles on the membrane filter were observed and
identified using a scanning electron microscope JSM5600LV coupled to an energy dispersion spectroscope
JEO-2200 (JMS, Tokyo, Japan). Statistical differences
were analyzed by the Wilcoxon U-test.

RESULTS
Table 1 shows the mean (range) of particles in
glycyrrhizin injection samples of a total of 100 glass
ampoules (5 companies) and 120 plastic ampoules (6
companies). In the injection samples of glass ampoules,
the number of particles with a diameter of 1.3- < 5 µm
was 252.9/mL, that of particles with a diameter of 5- <
10 µm was 12.5/mL, that of particles with a diameter
of 10- < 50 µm was 3.2/mL, and that of particles with
a diameter of 50- < 100 µm was 0.09/mL. In injection
samples of plastic ampoules, the mean number of particles with a diameter of 1.3- < 5 µm was 43.04/mL, that of
particles with a diameter of 5- < 10 µm was 2.11/mL, that
of particles with a diameter of 10- < 50 µm was 0.59/mL,
and that of particles with a diameter of 50- < 100 µm was
0/mL. The number of particles was significantly higher

Table 1. The mean (range) of particles at each diameter in glycyrrhizin injections contained in glass and plastic ampoules
Particle diameter (µm)
1.3 - < 5 μm

5 - < 10 μm

10 - < 50 μm

50 - 100 μm

Glass ampoule preparation
Pharmaceutical company (A) (n=20)

293.4 (145-523)

12.45 (5-25)

3.8 (1-10)

0.15 (0-1)

Pharmaceutical company (B) (n=20)

166.15 (91-228)

5.45 (1-13)

1.3 (0-4)

0

Pharmaceutical company (C) (n=20)

331.65 (197-523)

17.75 (6-28)

3.95 (1-8)

0.15 (0-1)

Pharmaceutical company (D) (n=20)

121.6 (70-203)

5.55 (0-12)

1.95 (0-7)

0.05 (0-1)

Pharmaceutical company (E) (n=20)

351.95 (153-628)

21.65 (8-42)

5.05 (1-17)

0.1 (0-1)

Total (n = 100)

252.95*(70-628)

12.57*(0-42)

3.21*(0-17)

0.09 (0-1)

Pharmaceutical company (A) (n=20)

57.95 (27-93)

1.55 (0-3)

0

0

Pharmaceutical company (B) (n=20)

44.45 (17-89)

1.7 (0-3)

0

0

Pharmaceutical company (F) (n=20)

39.75 (16-98)

2.3 (0-9)

1.05 (0-6)

0

Pharmaceutical company (G) (n=20)

45.7 (14-81)

3.55 (0-8)

1.45 (0-3)

0

Pharmaceutical company (H) (n=20)

36.2 (12-93)

1.75 (0-9)

0.5 (0-3)

0

Pharmaceutical company (I) (n=20)

34.2 (11-72)

1.8 (0-8)

0.55 (0-3)

0

Total (n = 120)

43.04 (11-98)

2.11 (0-9)

0.59 (0-6)

0

Plastic ampoule preparation

*P < 0.0001
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in the injection samples of glass than in those of plastic
ampoules ( p < 0.0001).
Figure 1 shows scanning electron micrographs of
three types of particles on the membrane filters after the
filtration of glycyrrhizin injection samples following the
cutting of glass ampoules and results of the identification of these particles by energy dispersion spectroscopy. Since X-ray analysis of particles on membrane filters
showed a large amount of Si, these particles were identified as glass fragments. No particles were observed on
membrane filters after the filtration of glycyrrhizin injection samples following the cutting of plastic ampoules.

DISCUSSION
One of the widely employed drugs for injection via
peripheral veins is glycyrrhizin used for type C hepatitis. In general, glycyrrhizin for injection is administered
as an intravenous injection or drip at a general dose of
40-100 mL (2-5 ampoules of 20 mL injection) once daily
for the first 1 month and 2-3 times weekly for the subsequent 3 months or more. Thus, since glycyrrhizin for
injection is administered at a large total dose for a long
period, when glass ampoules are used for a long period,
the risk of glass fragment accumulation in the body is
high. Glycyrrhizin injection is used in more than 80% of
Japanese hospitals, with about 52 million ampoule glycyrrhizin injections in 2007. Usage ratio of glass ampoules
and plastic ampoules is 50% vs. 50%. Glass ampoules of
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Figure 1. Identification of three types of particles by scanning electron microscopy and energy dispersion spectroscopy (A), (B) and (C) are
glass fragments.
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In general, since the pressure inside glass ampoule
is negative due to heat sealing, glass fragments at the
time of ampoule cutting are drawn into the ampoule.
Indeed, this survey revealed the mixture of a large
amount of glass fragments in glycyrrhizin samples after
glass ampoule cutting. Most glass fragments were within
a diameter of 1.3-5 µm. Since the limit of particles that
can be visually observed is 40-50 µm, the detection of
glass fragments with a diameter of 1.3-5 µm in injections
contained in glass ampoules is difficult. Even if ampoules
are cut and left for 3 minutes after ampoule cutting, glass
fragments with a diameter of 1.3-5 µm may not settle but
remain suspended in injections. Therefore, at the time
of aspiration of injections using a syringe, there is a risk
of the aspiration of glass fragments with a diameter of
1.3-5 µm suspended in injections after ampoule cutting.
In fact, our previous study clearly showed that a large
amount of glass fragments in total parenteral nutrition or
intravenous infusion admixed with glass ampoule drugs
were detected (9,10). This result was consistent with our
previous study that most of glass fragments were with a
diameter of 1.3-5 µm.
It is ideal to filtrate injections after cutting glass
ampoules using a membrane filter to remove particles
such as glass fragments in a clean bench or safety cabinet
by a pharmacist immediately before injection. However,
such a procedure is not realistic in terms of labor, time
and cost. Injection needles with a filter can be used, but
this filter allows the removal of particles with a diameter
of 10 µm or more but not those of 1.3-5 µm. This survey
revealed the presence of a mixture of a large amount of
glass fragments with a diameter of 1.3-5 µm that can not
be macroscopically observed in injection samples after
the cutting of glass ampoules. In injection samples of
plastic ampoules, no particles such as glass fragments
were observed after ampoule cutting, and the number of
particles was much lower than that in injection samples
of glass ampoules. Plastic containers include those made
of polypropylene or polyvinyl chloride. To improve moldability, a plasticizer such as diethylhexyl phthalate and
phthalate has been added to these containers. This plasticizer sometimes leaches from plastic containers into
injections, causing particles. Therefore, plastic containers without diethylhexyl phthalate should be selected for
injections. The material of plastic ampoules in Japan is
mostly low-density polyethylene without diethylhexyl
phthalate. Since the material of all plastic ampoules
for glycyrrhizin injections investigated in this study
was low-density polyethylene, particle contamination
due to leaching of the components of plastic containers was unlikely. On the other hand, in glass ampoules,
ion exchange between Na+ and H- ions in glass occurs,
and Na+ ions in glass are transferred into injections and
bind to OH- ions, forming NaOH. As a result, the injection becomes alkaline, and pH-associated incompatibility
of combined drugs may reduce the main drug content or
induce sedimentation, resulting in particle formation. In

addition, glass ampoules involve the risk of injury at the
time of ampoule cutting.
Glass fragments in injections can potentially cause
fatal pulmonary thrombosis. When particles cannot be
removed using filters by pharmacists, it is desirable to
use injection containers with no risk of contamination or
injury at the time of ampoule cutting, which may occur
using glass ampoules. Therefore, for the prevention of
particle contamination and safe ampoule cutting, the use
of plastic rather than glass ampoules is recommended for
glycyrrhizin injections that are administered at a high
dose for a long period.
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